In companion animal practice, Quqiu Powder Veterinary Grade API is frequently converted into direct compression tablets for oral administration to dogs and cats at label strengths between 5 mg and 40 mg per unit. The direct compression route is selected only after the API powder meets sieved fraction criteria: D90 ≤250 µm, tapped density 0.55–0.75 g/mL, loss on drying ≤1.0%, and Hausner ratio ≤1.35. The formulation is built around a two-part geometric pre-blend: Quqiu is first passed through a 600 µm screen with an equal mass of microcrystalline cellulose PH102, then blended in a 500 L V-shell blender at 12 rpm for 10 minutes. The main fillers—lactose monohydrate 200 mesh and crospovidone 2.0–5.0% w/w—are added and blended for an additional 15 minutes; magnesium stearate is sifted through a 500 µm screen and added at 0.5–1.0% w/w in the final 3 minutes. Compression is performed on a 27-station rotary press with a pre-compression roller set at 4–6 kN and main compression 8–15 kN. Tablets are checked for mass uniformity, thickness 2.8–3.6 mm, hardness 50–80 N, and friability ≤0.5% per USP <1216>. Blend uniformity acceptance value remains ≤15 per USP <905> and Ph. Eur. 2.9.40; assay is 95.0–105.0% of label claim. Dissolution is run on 6 tablets in 900 mL of 0.01 M HCl at 37 °C with paddle speed 50 rpm, and the Q threshold is 80% dissolved at 45 minutes. Because low-dose direct compression blends are sensitive to over-lubrication, the final blend is discharged from the V-shell only after the magnesium stearate addition has been kept below 1.0% w/w; blends with higher lubricant content have shown reduced tensile strength and capping during production runs. The finished tablets are packaged in PVC/PVdC-aluminium blisters with a desiccant, and batch records document in-process checks at 20-minute intervals in accordance with 21 CFR 211.110.

What Controls Endotoxin Limits in Lyophilized Quqiu Injection Concentrates?

For injectable use, Quqiu Powder is not directly filled as a dry powder unless it is subsequently lyophilized and terminally sealed under aseptic conditions. The bulk solution is compounded in water for injection at a concentration equivalent to 10–50 mg/mL after reconstitution. The formulation vector includes mannitol 4–6% w/v or trehalose dihydrate 5–8% w/v as a lyoprotectant and a citrate buffer system holding pH at 4.0–5.5. The solution is passed through a 0.45 µm clarification filter then a 0.22 µm PVDF sterilising filter. The filtrate is filled into 10 mL type I borosilicate vials with a fill volume of 5.0 mL. Lyophilization proceeds with freezing at −40 °C for 4 hours, primary drying at shelf temperature −30 °C and chamber pressure 0.200 mbar for 36–48 hours, and secondary drying at +25 °C until residual moisture is ≤1.0%. Endotoxin control begins with the API powder; the injectable grade should carry a certificate with bacterial endotoxins ≤0.5 EU/mg and bioburden ≤100 CFU/g before sterilization. Terminal steam sterilization at 121 °C is generally avoided for this product class because of the risk of hydrolytic degradation above pH 6.0; aseptic processing is therefore maintained in accordance with 21 CFR 211.113. Filling, stoppering, and capping are conducted in a restricted-access barrier with a Grade A critical zone and Grade C background, equivalent to ISO 14644-1 Class 5 and Class 7 respectively. The finished lyophile is reconstituted with WFI and tested for sterility per USP <71> and Ph. Eur. 2.6.1, particulate matter per USP <788> with limits of ≤6000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm, and osmolality in the range 290–330 mOsm/kg for small-animal peripheral administration. The injection is presented as a single-dose lyophilized vial with a reconstitution diluent; no antimicrobial preservative is included. Published long-term stability data for this specific Quqiu lyophilized configuration is limited; forced degradation and photostability studies under VICH GL3 are required before assigning a retest period exceeding 24 months.

If Quqiu Powder Is Filled into Hard Gelatin Capsules Below a 100 mg Fill Weight

When dose titration requires strength flexibility between 10 mg and 100 mg, hard gelatin capsule formulations of Quqiu are used for equine and companion animal dosing. The API is pre-blended with lactose monohydrate 200 mesh and pregelatinized starch in a 100 L bin blender at 10 rpm for 20 minutes; colloidal silicon dioxide at 0.5–1.0% w/w is added to improve flow because micronized Quqiu powder tends to coat blender surfaces and reduce batch-to-batch recovery. Automatic capsule filling on a dosator machine with a size 3 or size 4 capsule is operated at fill weights of 90–150 mg; fill weight RSD is held at ≤2.0% across 30 samples. Weight variation is assessed per USP <905> with acceptance limits of ±10% for fills of 120–300 mg; potencies are controlled to 95.0–105.0% of label claim. Dissolution is performed in 900 mL water at 37 °C using apparatus 2 with sinkers at 50 rpm; the acceptance criterion is Q=75% dissolved at 60 minutes. If Quqiu has poor intrinsic wettability, the dry blend may include sodium lauryl sulfate at 0.5–1.0% w/w, but this must be evaluated against capsule shell incompatibility and pinhole formation. The filled capsules are dedusted and banded; banding reduces fill weight loss and improves tamper evidence. Low-dose capsule blends are sampled at the beginning, middle, and end of the filling run for content uniformity, and any blend segregation observed as an RSD above 5.0% triggers a re-blending step with additional 5-minute bin rotation.

Across swine and poultry operations, oral top-dress powder formulations containing Quqiu are diluted with anhydrous dextrose or maltodextrin before being dispersed over feed, because the direct API powder at therapeutic doses frequently requires dose administration accuracy within ±5% of the target mg/kg. The carrier is selected with a tapped density between 0.60 g/mL and 0.65 g/mL to match the API’s bulk density and reduce vertical segregation during drum transfer. Geometric dilution is performed in a 200 kg ribbon mixer with paddle tip speed 1.5 m/s for 20 minutes; the first pre-blend mixes Quqiu with an equal weight of carrier, and subsequent additions double the batch size until the final ratio is reached, commonly 1:19 or 1:39 depending on the prescribed dose. The final blend is sampled from 10 locations with a sampling thief, and the acceptance criterion is an RSD ≤5.0% with individual samples within 90.0–110.0% of target potency. Moisture is controlled below 1.0% LOD, and the sachet fill operation is performed at relative humidity ≤35% RH to prevent clumping. The finished sachets are sealed in aluminium foil laminate and include a desiccant unit. Dust extraction is used at the blending discharge because fine Quqiu powder tends to remain airborne during transfer; the engineering control is validated to the site occupational exposure limit. The top-dress product is labelled with a withdrawal period derived from tissue residue studies under VICH GL48 or equivalent regional requirements.

Wet Granulation End-Point Torque and Post-Drying Granule Size Distribution

Because the as-supplied Quqiu powder may exhibit poor flow or segregation tendency, high-shear wet granulation is performed in a 10 L bowl with impeller speed 300 rpm and chopper speed 1500 rpm; the binder is polyvinylpyrrolidone K30 dissolved in purified water at 5% w/w. Granulation endpoint is monitored by impeller torque and power consumption because the transition from wetted mass to dense granules occurs over a narrow moisture window, typically 8–12% water content. The target endpoint is a torque rise of 1.5–2.0 N·m above the dry-mix baseline, corresponding to a cohesive mass that forms granules without overwetting. During extrusion-spheronization, the wet mass is forced through a 0.8 mm screen at screw speed 45 rpm and spheronized at 900 rpm for 3–5 minutes. Wet granules are dried in a fluid bed at inlet air temperature 50 °C until loss on drying is 1.5–2.0%. Sieve analysis is performed with a stack of 850 µm, 425 µm, and 150 µm screens; the specification retains granules in the 150–850 µm fraction at ≥70% w/w. The dried granules are mixed with extragranular crospovidone and magnesium stearate before compression or with a carrier before filling into pouches. Overgranulation produces a dense granule population with tap density exceeding 0.80 g/mL, which can cause capping during tableting; undergranulation leaves fine particles below 150 µm and creates segregation risk.

Premix manufacturing for medicated feed involves blending Quqiu into a carrier system that must retain homogeneity from the mixer through bulk bin discharge and auger transfer. Quqiu premix batches are typically manufactured at 0.5–5.0% active concentration using ground rice hulls, calcium carbonate, or corn cob fractions as carriers. The carrier is selected with a particle size range of 200–800 µm and low fines content below 150 µm, because particle-size mismatch between API and carrier drives segregation under vibration. A 1000 kg double-ribbon mixer is charged with the carrier and a mineral oil spray at 1–2% w/w to reduce dust and improve adhesion of Quqiu particles. Mixing time is 15–20 minutes at 25 rpm; blend uniformity is sampled from 10 points with a thief and tested by HPLC, with acceptance RSD ≤5.0%. The final premix is discharged into bulk bags and sealed with polyethylene liners to limit moisture ingress. Mass-flow bin design is preferred over funnel-flow because funnel-flow discharge creates a first-in/last-out sequence that magnifies segregation. In-process records include cleaning verification because Quqiu residues in medicated feed can contaminate non-target species if carryover is not controlled under 21 CFR 225.58. The following table summarizes operational variables and acceptance criteria for a 0.5% premix run.

Water-Soluble Quqiu Powder for Drinking Medication Relies on Effervescent Dispersion and Hardness Tolerance

In mass medication of pigs and poultry, Quqiu drinking water formulations are prepared as water-soluble powders or effervescent granules. The formulation contains citric acid monohydrate at 40–60% w/w and sodium bicarbonate at 30–50% w/w, plus poloxamer 188 at 0.5–1.0% w/w as a wetting agent; Quqiu active is incorporated at a concentration corresponding to 100–500 g per 25 kg bag. The dry blend is granulated in a fluid bed, and the final granules are controlled for dispersibility: 5.0 g of product must disperse in 1.0 L of water at 20 °C within 3 minutes without foam collapse or precipitate. Effervescent reaction produces a pH of 3.5–4.5, which supports solubility and reduces microbial growth during the medication period. Drinking water hardness up to 500 mg/L CaCO3 is compensated with sodium citrate at 2–4% w/w to prevent calcium salt precipitation. Stock solutions are administered through a proportioner pump set at 1:100 or 1:200, yielding final drinking water concentrations between 10 mg/L and 200 mg/L depending on species and target dose. The finished powder is packed in aluminium-lined multiwall paper sacks with moisture barrier; bulk density is controlled at 0.50–0.70 g/mL to ensure consistent dosing by volumetric cup. Because residual moisture above 2.0% prematurely triggered effervescence during storage, batch records specify drying at 45 °C until LOD ≤1.0% and sealing at ≤35% RH.